Duquesne Family Office LLC Trims Stock Holdings in Ascendis Pharma A/S $ASND

Key Points

• Duquesne Family Office LLC reduced its holdings in Ascendis Pharma A/S by 40.1%, now owning approximately 158,720 shares valued at $24.74 million.
• Ascendis Pharma A/S reported earnings of ($0.93) per share for the latest quarter, beating expectations significantly and generating revenue of $216.28 million.
• Analyst price targets for Ascendis Pharma A/S have been raised, with a consensus target price of $244.36 and a majority rating of "Buy" from fifteen equities research analysts.

Duquesne Family Office LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 40.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 158,720 shares of the biotechnology company's stock after selling 106,320 shares during the quarter. Duquesne Family Office LLC owned about 0.26% of Ascendis Pharma A/S worth $24,738,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC increased its stake in Ascendis Pharma A/S by 413.1% in the first quarter. HighTower Advisors LLC now owns 18,032 shares of the biotechnology company's stock valued at $2,810,000 after purchasing an additional 14,518 shares during the last quarter. Pursue Wealth Partners LLC acquired a new position in Ascendis Pharma A/S in the first quarter valued at $226,000. Sigma Planning Corp acquired a new position in Ascendis Pharma A/S in the first quarter valued at $236,000. Diversify Advisory Services LLC acquired a new position in Ascendis Pharma A/S in the first quarter valued at $332,000. Finally, Braidwell LP acquired a new position in Ascendis Pharma A/S in the first quarter valued at $16,632,000.

Ascendis Pharma A/S Stock Down 0.3%

Shares of NASDAQ ASND traded down $0.69 on Monday, hitting $205.22. The company had a trading volume of 608,323 shares, compared to its average volume of 490,958. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $208.16. The business has a 50 day moving average of $182.68 and a two-hundred day moving average of $168.05. The firm has a market capitalization of $12.56 billion, a P/E ratio of -39.77 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASND has been the subject of several analyst reports. Wedbush upped their target price on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Cantor Fitzgerald upped their target price on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley assumed coverage on Ascendis Pharma A/S in a research note on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price target for the company. Citigroup restated a "buy" rating and set a $290.00 price target (up from $243.00) on shares of Ascendis Pharma A/S in a research note on Friday, August 8th. Finally, JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 19th. Fifteen analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $244.36.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.